Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Reneo Pharmaceuticals Inc (RPHM)

Reneo Pharmaceuticals Inc (RPHM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,813
  • Shares Outstanding, K 33,421
  • Annual Sales, $ 0 K
  • Annual Income, $ -77,390 K
  • 60-Month Beta 0.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.63
Trade RPHM with:

Options Overview Details

View History
  • Implied Volatility 494.29% ( -52.38%)
  • Historical Volatility 32.16%
  • IV Percentile 97%
  • IV Rank 81.58%
  • IV High 603.75% on 02/06/24
  • IV Low 9.54% on 03/25/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 21
  • Volume Avg (30-Day) 28
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 2,951
  • Open Int (30-Day) 3,027

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.37
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.54
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +38.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6200 +3.09%
on 04/25/24
1.9200 -13.02%
on 04/17/24
+0.0200 (+1.21%)
since 03/26/24
3-Month
1.5500 +7.74%
on 03/13/24
1.9200 -13.02%
on 04/17/24
+0.0200 (+1.21%)
since 01/26/24
52-Week
0.9801 +70.39%
on 12/14/23
10.9800 -84.79%
on 05/01/23
-8.3000 (-83.25%)
since 04/26/23

Most Recent Stories

More News
Shortened Week Due to Easter Holiday

Monday U.S. Economic Lookahead New home sales (Feb.) Featured Earnings PVH Corp. (NYSE: ...

PVH : 111.03 (+0.22%)
RPHM : 1.6700 (+1.21%)
MKC : 75.73 (+0.22%)
GME : 11.90 (+6.16%)
PRGS : 50.34 (-0.71%)
CTAS : 666.23 (+0.15%)
PAYX : 119.97 (-1.64%)
CCL : 15.08 (-0.66%)
WBA : 17.70 (+0.57%)
MSM : 93.22 (-0.01%)
OXM : 106.71 (+0.91%)
NOVC.TO : 1.36 (+1.49%)
Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results

IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the...

RPHM : 1.6700 (+1.21%)
Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors

IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the...

RPHM : 1.6700 (+1.21%)
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates

LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies (PMM)...

RPHM : 1.6700 (+1.21%)
Reneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IRVINE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the...

RPHM : 1.6700 (+1.21%)
Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results

IRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the...

RPHM : 1.6700 (+1.21%)
Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

IRVINE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the...

RPHM : 1.6700 (+1.21%)
Reneo Pharmaceuticals Announces Senior Leadership Promotions

Michael P. Cruse appointed Chief Operating OfficerJennifer P. Lam appointed Principal Financial and Accounting Officer IRVINE, Calif., March 07, 2022 ...

RPHM : 1.6700 (+1.21%)
Reneo Pharmaceuticals Enters Oversold Territory (RPHM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

RPHM : 1.6700 (+1.21%)
Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference

IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the...

RPHM : 1.6700 (+1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 1.7493
2nd Resistance Point 1.7295
1st Resistance Point 1.6997
Last Price 1.6700
1st Support Level 1.6501
2nd Support Level 1.6303
3rd Support Level 1.6005

See More

52-Week High 10.9800
Fibonacci 61.8% 7.1600
Fibonacci 50% 5.9800
Fibonacci 38.2% 4.8001
Last Price 1.6700
52-Week Low 0.9801

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar